Sciatica Treatment Market By Type, By Drug class, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

List of Tables

The sciatica treatment market size was valued for $678.02 million in 2021 and is estimated to reach $991.26 million by 2031, exhibiting a CAGR of 3.9% from 2022 to 2031.

Sciatica is referred to the pain that mainly affects sciatic nerves whereas sciatic nerves are the nerves that travel from the lower back through the hips and buttocks and down through each leg. Sciatica usually affects only one side of the lower body but the pain can occur in any part of the nerve pathway from the lower back to the buttock and the back of a thigh and calf. Furthermore, common symptoms of sciatica include pain in the leg which may worsen when sitting, burning or tingling down the leg, shooting pain that makes it difficult for the person to stand. Moreover, the pain may also occur in foot and toes, depending on the part of sciatic nerve affected. Sciatica can be treated using various medications or analgesic drugs. The medications include anti-inflammatory drugs, analgesic drugs, anti-convulsant and others.

Major factors that drive the growth of the sciatica treatment market include increase in incidence of sciatica, surge in R&D activities for developing novel therapeutics for sciatica and rise in awareness among the people regarding sciatica and its treatments. There is an increase in incidence of sciatica in the developing and developed countries which have many different causes. Sciatica is mainly caused due to herniated or slipped disk, degenerative disk, spinal stenosis, spondylolisthesis and others. According to the Johns Hopkins Arthritis Center, in the recent population estimates indicate that the prevalence of ankylosing spondylitis (AS) in the U.S. is approximately 0.2-0.5% and based on data from multiple countries, the age- and sex-adjusted incidence of ankylosing spondylitis (AS) is 0.4-14 per 100,000 people.

In addition, in a year about 2% of people get a herniated disk. When a herniated disk happens to a vertebra in lower back, it can press on the sciatic nerve leading to sciatica. Thus, huge prevalence of such conditions leads to increase in incidences of sciatica. This, in turn, propels the growth of the sciatica treatment market.

In addition, increase in R&D activities in pharmaceutical field is driving the growth of the market. Major players are focusing on developing new drugs and APIs having application in sciatica treatment that are potent and efficient. Moreover, there is an increase in outsourcing research activities by the pharmaceutical companies to academic and private contract research organizations (CROs), which allows the company to stay competitive and flexible in a world of increasingly advanced technologies. This supports the key market players to develop novel drug therapies for sciatica and other diseases, which further propels the growth of the market.

Although, various key factors are driving the growth of the market, few factors such as lack of specific approved treatments for sciatica and presence of alternate treatment options hinder the growth of the market. Alternate treatment options including the physiotherapy, and bracing along with surgical treatment restrict the growth of the sciatica treatment market. However, emerging economies of Asia-Pacific and LAMEA present lucrative opportunities for market players for investments. For instance, countries such as China and India with huge population base and high patient pool offer lucrative opportunities for the market growth.

The sciatica treatment market is segmented by type, treatment, distribution channel and region. By type, the market is categorized into acute sciatica, chronic sciatica and others. On the basis of drug class, the market is segregated into non-steroidal anti-inflammatory drug (NSAIDs), steroids, antidepressants, and others. On the basis of distribution channel, the market is categorized into hospital pharmacies, retail and specialty pharmacies and online providers.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the Abbott, Alkem Laboratories Limited, Amneal Pharmaceuticals LLC., Aurobindo Pharma, Johnson & Johnson, Sinfonia Biotherapeutics, Sorrento Therapeutics, Inc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited and Zydus Group.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the sciatica treatment market analysis from 2021 to 2031 to identify the prevailing sciatica treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the sciatica treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global sciatica treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

Acute sciatica
Chronic sciatica
Others

By Drug class

Non-steroidal anti-inflammatory drugs
Steroids
Antidepressants
Others

By Distribution channel

Hospital pharmacies
Retail and specialty pharmacies
Online providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players

Abbott Laboratories
Teva Pharmaceutical Industries Limited
Aurobindo Pharma
Sorrento Therapeutics, Inc
Alkem Laboratories Ltd
Amneal Pharmaceuticals LLC
Johnson and Johnson
Sun Pharmaceutical Industries Ltd.
Sinfonia Biotherapeutics
Zydus Lifesciences Limited

Product Code: A13379

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. High bargaining power of suppliers
- 3.3.2. Moderate bargaining power of buyers
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate threat of new entrants
- 3.3.5. Moderate intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in incidence of sciatica
  - 3.4.1.2. Increase in geriatric population
  - 3.4.1.3. Increase in R&D activities
- 3.4.2. Restraints
  - 3.4.2.1. Presence of alternate treatment
- 3.4.3. Opportunities
  - 3.4.3.1. Growth opportunity in emerging markets
3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: SCIATICA TREATMENT MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Acute sciatica
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Chronic sciatica
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Others
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: SCIATICA TREATMENT MARKET, BY DRUG CLASS

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Non-steroidal anti-inflammatory drugs
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Steroids
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Antidepressants
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Others
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country

CHAPTER 6: SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Retail and specialty pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Online providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: SCIATICA TREATMENT MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Type
- 7.2.3. Market size and forecast, by Drug class
- 7.2.4. Market size and forecast, by Distribution channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Type
  - 7.2.5.1.3. Market size and forecast, by Drug class
  - 7.2.5.1.4. Market size and forecast, by Distribution channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Type
  - 7.2.5.2.3. Market size and forecast, by Drug class
  - 7.2.5.2.4. Market size and forecast, by Distribution channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Type
  - 7.2.5.3.3. Market size and forecast, by Drug class
  - 7.2.5.3.4. Market size and forecast, by Distribution channel
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Type
- 7.3.3. Market size and forecast, by Drug class
- 7.3.4. Market size and forecast, by Distribution channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Type
  - 7.3.5.1.3. Market size and forecast, by Drug class
  - 7.3.5.1.4. Market size and forecast, by Distribution channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Type
  - 7.3.5.2.3. Market size and forecast, by Drug class
  - 7.3.5.2.4. Market size and forecast, by Distribution channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Type
  - 7.3.5.3.3. Market size and forecast, by Drug class
  - 7.3.5.3.4. Market size and forecast, by Distribution channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Type
  - 7.3.5.4.3. Market size and forecast, by Drug class
  - 7.3.5.4.4. Market size and forecast, by Distribution channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Type
  - 7.3.5.5.3. Market size and forecast, by Drug class
  - 7.3.5.5.4. Market size and forecast, by Distribution channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Type
  - 7.3.5.6.3. Market size and forecast, by Drug class
  - 7.3.5.6.4. Market size and forecast, by Distribution channel
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Type
- 7.4.3. Market size and forecast, by Drug class
- 7.4.4. Market size and forecast, by Distribution channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Type
  - 7.4.5.1.3. Market size and forecast, by Drug class
  - 7.4.5.1.4. Market size and forecast, by Distribution channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Type
  - 7.4.5.2.3. Market size and forecast, by Drug class
  - 7.4.5.2.4. Market size and forecast, by Distribution channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Type
  - 7.4.5.3.3. Market size and forecast, by Drug class
  - 7.4.5.3.4. Market size and forecast, by Distribution channel
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Type
  - 7.4.5.4.3. Market size and forecast, by Drug class
  - 7.4.5.4.4. Market size and forecast, by Distribution channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Type
  - 7.4.5.5.3. Market size and forecast, by Drug class
  - 7.4.5.5.4. Market size and forecast, by Distribution channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Type
  - 7.4.5.6.3. Market size and forecast, by Drug class
  - 7.4.5.6.4. Market size and forecast, by Distribution channel
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Type
- 7.5.3. Market size and forecast, by Drug class
- 7.5.4. Market size and forecast, by Distribution channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Type
  - 7.5.5.1.3. Market size and forecast, by Drug class
  - 7.5.5.1.4. Market size and forecast, by Distribution channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Type
  - 7.5.5.2.3. Market size and forecast, by Drug class
  - 7.5.5.2.4. Market size and forecast, by Distribution channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Type
  - 7.5.5.3.3. Market size and forecast, by Drug class
  - 7.5.5.3.4. Market size and forecast, by Distribution channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Type
  - 7.5.5.4.3. Market size and forecast, by Drug class
  - 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

9.1. Abbott Laboratories
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Alkem Laboratories Ltd
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. Amneal Pharmaceuticals LLC
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. Johnson and Johnson
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
9.5. Sinfonia Biotherapeutics
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Key strategic moves and developments
9.6. Sorrento Therapeutics, Inc
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. Sun Pharmaceutical Industries Ltd.
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. Zydus Lifesciences Limited
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. Teva Pharmaceutical Industries Limited
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Aurobindo Pharma
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance